Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations.
暂无分享,去创建一个
[1] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[2] T. Perez,et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD , 2008, International journal of chronic obstructive pulmonary disease.
[3] D. Price,et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. , 2008, Primary care respiratory journal : journal of the General Practice Airways Group.
[4] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[5] J. Bourbeau,et al. Impact on patients’ health status following early identification of a COPD exacerbation , 2007, European Respiratory Journal.
[6] D. Niewoehner,et al. Premature discontinuation of patients: a potential bias in COPD clinical trials , 2007, European Respiratory Journal.
[7] G. Donaldson,et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD , 2007, European Respiratory Journal.
[8] F. Maltais,et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials , 2007, Thorax.
[9] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[10] J. Maurer. Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial , 2007 .
[11] F. Maltais,et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.
[12] J. Bourbeau,et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis , 2006, Thorax.
[13] D. Dusser,et al. The effect of tiotropium on exacerbations and airflow in patients with COPD. , 2006, The European respiratory journal.
[14] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[15] C. Lenfant,et al. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .
[16] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[17] R. Casaburi,et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. , 2005, Chest.
[18] Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. , 2004, Thorax.
[19] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[20] S. Ramsey,et al. The burden of illness and economic evaluation for COPD , 2003, European Respiratory Journal.
[21] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[22] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[23] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[24] M. Leinonen,et al. Pneumonic vs Nonpneumonic Acute Exacerbations of COPD , 2002, Chest.
[25] T. Seemungal,et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.
[26] S. Quintana,et al. Mortality after hospitalization for COPD. , 2002, Chest.
[27] R. Zuwallack,et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.
[28] M. Malesker,et al. Pharmacoeconomic evaluation of COPD. , 2000, Chest.
[29] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[30] Stephen Senn,et al. The Many Modes of Meta , 2000 .
[31] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[32] R. Kay. Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.
[33] L Goldman,et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.